Literature DB >> 35349726

PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.

Eduardo Vilar-Gomez1, Carlos J Pirola2, Silvia Sookoian2, Laura A Wilson3, Tiebing Liang1, Naga Chalasani1.   

Abstract

BACKGROUND AND AIMS: It is unclear whether rs738409 (p.I148M) missense variant in patatin-like phospholipase domain-containing 3 rs738409 promotes fibrosis development by triggering specific fibrogenic pathways or by creating an unfavorable microenvironment by promoting steatosis, inflammation, and ultimately fibrosis. We tested the hypothesis that intermediate histologic traits, including steatosis, lobular and portal inflammation, and ballooning may determine the effect of rs738409 on liver fibrosis among individuals with biopsy-proven NAFLD. APPROACH AND
RESULTS: Causal mediation models including multiple mediators in parallel or sequentially were performed to examine the effect of rs738409, by decomposing its total effect on fibrosis severity into direct and indirect effects, mediated by histology traits in 1153 non-Hispanic White patients. Total effect of rs738409 on fibrosis was β = 0.19 (95% CI: 0.09-0.29). The direct effect of rs738409 on fibrosis after removing mediators' effects was β = 0.09 (95% CI: 0.01-0.17) and the indirect effect of rs738409 on fibrosis through all mediators' effects were β = 0.010 (95% CI: 0.04-0.15). Among all mediators, the greatest estimated effect size was displayed by portal inflammation (β = 0.09, 95% CI: 0.05-0.12). Among different sequential combinations of histology traits, the path including lobular inflammation followed by ballooning degeneration displayed the most significant indirect effect (β = 0.023, 95% CI: 0.011-0.037). Mediation analysis in a separate group of 404 individuals with biopsy-proven NAFLD from other races and ethnicity showed similar results.
CONCLUSIONS: In NAFLD, nearly half of the total effect of the rs738409 G allele on fibrosis severity could be explained by a direct pathway, suggesting that rs738409 may promote fibrosis development by activating specific fibrogenic pathways. A large proportion of the indirect effect of rs738409 on fibrosis severity is mediated through portal inflammation.
© 2022 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35349726      PMCID: PMC9519813          DOI: 10.1002/hep.32491

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  44 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.

Authors:  Yaron Rotman; Christopher Koh; Joseph M Zmuda; David E Kleiner; T Jake Liang
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.

Authors:  John Zhong Li; Yongcheng Huang; Ruchan Karaman; Pavlina T Ivanova; H Alex Brown; Thomas Roddy; Jose Castro-Perez; Jonathan C Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

4.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.

Authors:  Luca Valenti; Mariagrazia Rumi; Enrico Galmozzi; Alessio Aghemo; Benedetta Del Menico; Stella De Nicola; Paola Dongiovanni; Marco Maggioni; Anna Ludovica Fracanzani; Raffaela Rametta; Massimo Colombo; Silvia Fargion
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

6.  Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Luca Valenti; Ahmad Al-Serri; Ann K Daly; Enrico Galmozzi; Raffaela Rametta; Paola Dongiovanni; Valerio Nobili; Enrico Mozzi; Giancarlo Roviaro; Ester Vanni; Elisabetta Bugianesi; Marco Maggioni; Anna Ludovica Fracanzani; Silvia Fargion; Christopher P Day
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

7.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros.

Authors:  Linda Valeri; Tyler J Vanderweele
Journal:  Psychol Methods       Date:  2013-02-04

9.  Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.

Authors:  Manju Kumari; Gabriele Schoiswohl; Chandramohan Chitraju; Margret Paar; Irina Cornaciu; Ashraf Y Rangrez; Nuttaporn Wongsiriroj; Harald M Nagy; Pavlina T Ivanova; Sarah A Scott; Oskar Knittelfelder; Gerald N Rechberger; Ruth Birner-Gruenberger; Sandra Eder; H Alex Brown; Guenter Haemmerle; Monika Oberer; Achim Lass; Erin E Kershaw; Robert Zimmermann; Rudolf Zechner
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

10.  Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease.

Authors:  Naga Chalasani; Laura Wilson; David E Kleiner; Oscar W Cummings; Elizabeth M Brunt; Aynur Unalp
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.